Patents by Inventor Joel M. Linden

Joel M. Linden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOSINE A2A AGONISTS FOR THE TREATMENT OF CYTOKINE STORM SYNDROME
    Publication number: 20230118877
    Abstract: The present invention relates methods of treating cytokine storm syndrome comprising administering to a patient in need thereof a therapeutically effective amount of an adenosine A2A receptor agonist.
    Type: Application
    Filed: June 2, 2022
    Publication date: April 20, 2023
    Inventors: Christine Lau, Yunge Zhao, Joel M. Linden, Barbara J. Mann, Preeti Chhabra, Kenneth Lewis Brayman, Sanford Feldman
  • Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
    Patent number: 8193200
    Abstract: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 5, 2012
    Assignees: University of Virginia Patent Foundation, Emory University
    Inventors: Shanthi V. Sitaraman, Joel M. Linden, Guoquan Wang, Robert Douglas Thompson, Jayson M. Rieger
  • Use of adenosine Amodulators to treat spinal cord injury
    Patent number: 8188063
    Abstract: The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one A2A receptor modulator to prevent injury to or enhance the healing of the injured cells.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 29, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Yuesheng Jason Li, Joel M. Linden, Jayson M. Rieger
  • Method to treat sickle cell disease
    Patent number: 8178509
    Abstract: The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: May 15, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Kori Wallace, Robert Alan Figler, Jayson M. Rieger
  • 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
    Patent number: 8158604
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 17, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
    Patent number: 8012484
    Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: September 6, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Courtney M. Lappas, Victor H. Engelhard
  • 2-propynyl adenosine analogs with modified 5?-ribose groups having A2A agonist activity
    Patent number: 7989431
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: August 2, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY
    Publication number: 20110136755
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Application
    Filed: February 15, 2011
    Publication date: June 9, 2011
    Applicant: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • 2-polycyclic propynyl adenosine analogs having A2A agonist activity
    Patent number: 7875595
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: January 25, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
  • 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF
    Publication number: 20100152127
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicant: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
  • 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
    Patent number: 7737127
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: June 15, 2010
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
  • 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY
    Publication number: 20090298788
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Application
    Filed: June 18, 2009
    Publication date: December 3, 2009
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
  • 2-propynyl adenosine analogs with modified 5?-ribose groups having Aagonist activity
    Patent number: 7605143
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: October 20, 2009
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • 2-polycyclic propynyl adenosine analogs having A2A agonist activity
    Patent number: 7576069
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: August 18, 2009
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
  • ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES
    Publication number: 20090170803
    Abstract: The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
    Type: Application
    Filed: April 10, 2003
    Publication date: July 2, 2009
    Inventors: Joel M. Linden, Gail W. Sullivan, W. Michael Scheld, Tom Gordon Obrig, Timothy L. MacDonald, Jayson M. Rieger
  • METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST
    Publication number: 20080312160
    Abstract: A therapeutic method for treating intestinal damage, enteritis, diarrhea, or a combination thereof caused by a C. difficile is provided. The method includes administration to a patient in need thereof an effective amount of an A2A adenosine receptor agonist, optionally in combination with an effective amount of a stable glutamine derivative, e.g., alanyl-glutamine.
    Type: Application
    Filed: April 9, 2008
    Publication date: December 18, 2008
    Inventors: Richard L. Guerrant, Joel M. Linden, Cirle A. Warren, Gail W. Sullivan, Timothy L. Macdonald
  • 2-polycyclic propynyl adenosine analogs having A2A agonist activity
    Patent number: 7442687
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: October 28, 2008
    Assignee: The University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
  • METHOD OF TREATING ISCHEMIA REPERFUSION INJURY BY INHIBING NKT CELL ACTIVITY
    Publication number: 20080254037
    Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).
    Type: Application
    Filed: March 25, 2008
    Publication date: October 16, 2008
    Applicant: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Courtney M. Lappas, Victor H. Engelhard
  • Method to reduce inflammatory response in transplanted tissue
    Patent number: 7427606
    Abstract: The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: September 23, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Kenneth Brayman, Gail W. Sullivan
  • Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
    Publication number: 20080176845
    Abstract: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
    Type: Application
    Filed: November 5, 2007
    Publication date: July 24, 2008
    Inventors: Shanthi V. Sitaraman, Joel M. Linden, Guoquan Wang, Robert Douglas Thompson, Jayson M. Rieger